secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANGIODYNAMICS INC (ANGO)
CIK:        0001275187
Form:       8-K
Filed at:   2023-01-05T23:59:59+00:00
Accession:  0000914121-23-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AngioDynamics Q2 FY2023 sales $85.4M (+9.1% YoY); GAAP loss $0.21/sh, adj EPS $0.01; reaffirms guidance
--------------------------------------------------------------------------------

- Net sales $85.4M, up 9.1% YoY; Med Tech +29.7% to $24.5M, Med Device +2.6% to $60.9M.
- GAAP net loss $0.21 per share; adjusted EPS $0.01 vs adjusted loss $0.02 a year ago.
- Adjusted EBITDA $7.5M, up from $4.4M in prior-year quarter.
- FY2023 guidance reaffirmed: net sales $342-348M, gross margin ~52.5-54.5%, adj EPS $0.01-$0.06.
- Cash $29.9M, $50M in debt; Preserve prostate cancer study enrollment passed midpoint.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1275187/000091412123000003/0000914121-23-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1275187/000091412123000003/an58427779-8ki.htm
  HTML page:      https://secwatch.observer/filing/0000914121-23-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer